

PRESS RELEASE

STRATEC – Chief Sales Officer to leave company

Birkenfeld, March 19, 2014

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announces that Bernd M. Steidle (Member, Board of Management, Marketing and Sales) has left the Board of Management as of March 19, 2014 and will have no further involvement in the company's operations.

The Supervisory Board and Board of Management of STRATEC would like to thank Mr. Steidle for his longstanding commitment and significant achievements on behalf of STRATEC and wishes him all the best in his future endeavours.

Company structures in the fields of marketing and sales will now be realigned under the management of company CEO Marcus Wolfinger. In future, the responsibilities for marketing and sales will be managed at senior vice president level. There are no plans to appoint a new member of the Board of Management with responsibility for sales and marketing in the near future.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:

STRATEC Biomedical AG

André Loy, Investor Relations

Gewerbestr. 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

ir@stratec.com

www.stratec.com